Docetaxel in the treatment of advanced non-small-cell lung cancer

References

• Ahmedin J, Siegel R, Ward E. Cancer statistics 2007. CA Cancer J. Clin.57, 43–66 (2007).
   Google Scholar
• Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer94(2), 153–156 (2001).
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Cox JD, Ginsberg RJ et al. NCCN non-small cell lung cancer practice guidelines. The National Comprehensive Cancer Network. Oncology (Huntingt.)10(Suppl. 11), 81–111 (1996).
   PubMedGoogle Scholar
• American Society of Clinical Oncology. Outcome of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology. J. Clin. Oncol.14(2), 671–679 (1996).
   PubMed Web of Science ®Google Scholar
• Pazdur R, Kudelka AP, Kavanagh JJ et al. The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat. Rev.19(4), 351–386 (1993).
   PubMed Web of Science ®Google Scholar
• Ringel I, Horwitz SB. Studies with RP 56976 (Taxotere): a semisynthetic analogue of Taxol. J. Natl Cancer Inst.83, 288–291 (1991).
   PubMed Web of Science ®Google Scholar
• Lavelle F, Bissery MC, Combeau C et al. Preclinical evaluation of docetaxel (Taxotere). Semin. Oncol.22(Suppl. 4), 3–16 (1995).
   Web of Science ®Google Scholar
• Hanauske A-R, Degen D, Hilsenbeck SG et al. Effects of Taxotere and Taxol on in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs3, 121–124 (1992).
   PubMed Web of Science ®Google Scholar
• Diaz JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by Taxol and Taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry32, 2747–2755 (1993).
   PubMed Web of Science ®Google Scholar
• Andreu JM, Diaz JF, Gil R et al. Solution structure of Taxotere-induced microtubules to 3 nm resolution. J. Biol. Chem.269, 31785–31792 (1994).
   PubMed Web of Science ®Google Scholar
• Riou J-F, Petitgenet O, Combeau C et al. Cellular uptake and efflux of docetaxel (Taxotere) and paclitaxel (Taxol) in P388 cell line. Proc. Am. Assoc. Cancer Res. USA (1994) (Abstract 385).
   Google Scholar
• Sawada N, Ishikava T, Fukase Y et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts. Clin. Cancer Res.4, 1013–1019 (1998).
   PubMed Web of Science ®Google Scholar
• Riou J-F, Naudin A, Lavelle F. Effects of Taxotere on murine and human tumor cell lines. Biochem. Biophys. Res. Commun.187, 164–170 (1992).
   PubMed Web of Science ®Google Scholar
• Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res.57, 229–233 (1997).
   PubMed Web of Science ®Google Scholar
• Guidolin D, Vacca A, Nussdorfer GG. A new image analysis method based on topological and fractal parameters to evaluate the angiostatic activity of docetaxel by using the Matrigel assay in vitro. Microvasc. Res.67(2), 117–124 (2004).
   PubMedGoogle Scholar
• Grant DS, Williams TL, Zahaczewsky M. Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int. J. Cancer104(1), 121–129 (2003).
   PubMed Web of Science ®Google Scholar
• Herbst RS, Khuri FR. Mode of action of docetaxel – a basis for combination with novel anticancer agents. Cancer Treat. Rev.29(5), 407–415 (2003).
   PubMed Web of Science ®Google Scholar
• Brooks TA, Minderman H, O’Loughlin KL et al. Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Mol. Cancer Ther.11, 1195–1205 (2003).
   Google Scholar
• Juliano R, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta455, 152–162 (1976).
   PubMed Web of Science ®Google Scholar
• Ueda K, Cornwell M, Gottesman M et al. The mdr1 gene, responsible for multidrug resistance, codes for P-glycoprotein. Biochem. Biophys. Res. Commun.141, 956–962 (1986).
   PubMed Web of Science ®Google Scholar
• Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl Cancer Inst.92, 1295–1202 (2000).
   PubMed Web of Science ®Google Scholar
• Ranganathan S, Benetatos CA, Colarusso PJ et al. Altered β-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br. J. Cancer77, 562–566 (1998).
   PubMed Web of Science ®Google Scholar
• Van Amerongen R, Berns A. TXR1-mediated thrombospondin repression: a novel mechanism of resistance to taxanes? Genes Dev.20, 1975–1981 (2006).
   PubMed Web of Science ®Google Scholar
• Extra JM, Rousseau F, Bruno R, Clavel M, Le Bail, Marty M. Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Treat. Rev.53(5), 1037–1042 (1993).
   Google Scholar
• Engels FK, Ten Tije AJ, Baker SD et al. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin. Pharmacol. Ther.75(5), 448–454 (2004).
   PubMed Web of Science ®Google Scholar
• Synold T, Newman E, Lenz H-J et al. Prospective evaluation of docetaxel (D) pharmacokinetics (PK) and toxicity in patients with tumor-related hepatic dysfunction (HD). Proc. Am. Soc. Clin. Oncol.18, 168a (1999) (Abstract 643).
   Google Scholar
• Pronk LC, Schellens JH, Planting AS et al. Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors. J. Clin. Oncol.15(3), 1071–1079 (1997).
   PubMedGoogle Scholar
• Millward MJ, Zalcberg J, Bishop JF et al. Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer. J. Clin. Oncol.15(2), 750–758 (1997).
   PubMed Web of Science ®Google Scholar
• Kunitoh H, Watanabe K, Onoshi T, Furuce K, Niitani H, Taguchi T. Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study. J. Clin. Oncol.14(5), 1649–1655 (1996).
   PubMed Web of Science ®Google Scholar
• Cerny T, Kaplan S, Pavlidis N et al. Docetaxel (Taxotere) is active in non-small-cell lung cancer: a Phase II trial of the EORTC Early Clinical Trials Group (ECTG). Br. J. Cancer70(2), 384–387 (1994).
   PubMed Web of Science ®Google Scholar
• Miller VA, Rigas JR, Francis PA et al. Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer75(4), 968–972 (1995).
   PubMed Web of Science ®Google Scholar
• Latreille J, Gelmon KA, Hirsh V et al. Phase II trial of docetaxel with dexamethasone premedication in patients with advanced non-small cell lung cancer: the Canadian experience. Invest. New Drugs16(3), 265–270 (1998).
   PubMedGoogle Scholar
• Fossella FV, Lee JS, Murphy WK et al. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J. Clin. Oncol.12(6), 1238–1244 (1994).
   PubMed Web of Science ®Google Scholar
• Francis PA, Rigas JR, Kris MG et al. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J. Clin. Oncol.12(6), 1232–1237 (1994).
   PubMed Web of Science ®Google Scholar
• Roszkowski K, Pluzanska A, Krzakowski M et al. A multicenter, randomized, Phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer27(3), 145–157 (2000).
   PubMed Web of Science ®Google Scholar
• Fossella FV, DeVore R, Kerr RN et al. Randomized Phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing regimens. The TAX 320 Non-Small Cell Lung Cancer Study group. J. Clin. Oncol.18(12), 2354–2362 (2000).
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol.18(10), 2095–2103 (2000).
   PubMed Web of Science ®Google Scholar
• Dancey J, Shepherd FA, Gralla RJ, Kim YS. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized Phase III trial. Lung Cancer43(2), 183–194 (2004).
   PubMed Web of Science ®Google Scholar
• Hanna N, Shepherd FA, Fossella FV et al. Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol.22(9), 1589–1597 (2004).
   PubMed Web of Science ®Google Scholar
• Douillard J, Kim E, Hirsh V et al. Gefitinib (Iressa) versus docetaxel in patients with locally advanced or metastatic non-small cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label Phase III study (INTEREST). J. Thorac. Oncol.2, S305 (Abstract PRS-02) (2007).
   Web of Science ®Google Scholar
• Fidias S, Dakhil A, Lyss D et al. Phase III study of immediate versus delayed docetaxel after induction therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer: updated report with survival. 2007 ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol.25(18 Suppl.) (2007) (Abstract LBA7516).
   Google Scholar
• Hainsworth JD, Burris HA III, Erland JB, Thomas M, Greco FA. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J. Clin. Oncol.16(6), 2164–2168 (1998).
   PubMed Web of Science ®Google Scholar
• Schuette W, Nagel S, Blankenburg T et al. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J. Clin. Oncol.23(33), 8389–8395 (2005).
   PubMed Web of Science ®Google Scholar
• Camps C, Massuti B, Jiménez A et al. Randomized Phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann. Oncol.17(3), 467–472 (2006).
   PubMed Web of Science ®Google Scholar
• Di Maio M, Perrone F, Chodini P et al. Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. J. Clin. Oncol.25(11), 1377–1382 (2007).
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med.346(2), 92–98 (2002).
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Zhu J, Sandier AB et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic non small cell lung carcinoma. Cancer92(10), 2639–2647 (2001).
   PubMed Web of Science ®Google Scholar
• Fossella F, Pereira JR, von Pawel J et al. Randomized, multinational, Phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J. Clin. Oncol.23(33), 8389–8395 (2005).
   Google Scholar
• Kubota K, Watanabe K, Kunitoh H et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J. Clin. Oncol.22(2), 254–261 (2004).
   PubMed Web of Science ®Google Scholar
• Lee WS, Bae BJ, Ryoo HM, Bae SH, Lee SC, Hyun DS. Efficacy of weekly docetaxel combined with platinum as first line treatment in patients with advanced non-small cell lung cancer. Eur. J. Cancer Suppl.5(4), 393 (2007).
   Google Scholar
• Booton R, Lorigan P, Anderson H et al. A Phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/ cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). Ann. Oncol.17(7), 1111–1119 (2006).
   PubMed Web of Science ®Google Scholar
• Alberola V, Camps C, Provencio M et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small cell lung cancer: a Spanish Lung Cancer Group Phase III randomized trial. J. Clin. Oncol.23(33), 8389–8395 (2005).
   Google Scholar
• Ardizzoni A, Boni L, Tiseo M et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J. Natl Cancer Inst.99(11), 847–857 (2007).
   PubMed Web of Science ®Google Scholar
• Rajeswaran A, Trojan A, Burnand B, Giannelli M. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer59(1), 1–11 (2008).
   PubMed Web of Science ®Google Scholar
• Georgoulias V, Ardavanis A, Aggelidou A et al. Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter Phase III trial. J. Clin. Oncol.22(13), 2602–2609 (2004).
   PubMed Web of Science ®Google Scholar
• Groen H, Schramel FM, Van der Hoeven JJM et al. Docetaxel and carboplatin once every 3 weeks versus weekly docetaxel in advanced non-small cell lung cancer (NSCLC). An interim analysis of a multicenter Phase III trial. Proc. Am. Soc. Clin. Oncol.22, 623 (2003) (Abstract 2505).
   Google Scholar
• Georgoulias V, Androulakis N, Kotsakis A et al. Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter Phase III trial. Lung Cancer59(1), 57–63 (2008). Georgoulias V, Ardavanis A, Aggelidou A et al. Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter Phase III trial. J. Clin. Oncol.22(13), 2602–2609 (2004).
   PubMed Web of Science ®Google Scholar
• Popa IE, Stewart K, Smith FP, Rizvi NA. A Phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced nonsmall cell lung carcinoma. Cancer95(8), 1714–1719 (2002).
   PubMedGoogle Scholar
• Israel V, Tagawa ST, Snyder T, Jeffers S, Raghavan D. Phase I/II trial of gemcitabine plus docetaxel in advanced non-small cell lung cancer (NSCLC). Invest. New Drugs22(3), 291–297 (2004).
   PubMedGoogle Scholar
• Rocha Lima CM, Rizvi NA, Zhang C et al. Randomized Phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC. Ann. Oncol.15(3), 410–418 (2004).
   PubMedGoogle Scholar
• Georgoulias V, Ardavanis A, Tsiafaki X et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a Phase III randomized trial. J. Clin. Oncol.23(13), 2937–2945 (2005).
   PubMed Web of Science ®Google Scholar
• Ziotopoulos P, Androulakis N, Mylonaki E et al. Front-line treatment of advanced non-small cell lung cancer with irinotecan and docetaxel: a multicentre Phase II study. Lung Cancer50(1), 115–122 (2005).
   Google Scholar
• Page RD, Smith FP, Geils GF et al. Prospective multi-center Phase II trial of docetaxel and vinorelbine with filgrastim support in subjects with advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol.22(Suppl. 14), 650S (2004) (Abstract 7138).
   Google Scholar
• American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J. Clin. Oncol.22(22), 330–353 (2004).
   PubMed Web of Science ®Google Scholar
• Georgoulias V, Papadakis E, Alexopoulos A et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet357(9267), 1478–1484 (2001).
   PubMed Web of Science ®Google Scholar
• Rigas J, Dragnev K, Kerry M et al. Survival equivalence of non-platinum based and platinum based chemotherapy for advanced non-small cell lung cancer (NSCLC): the results of a multicenter internet-based Phase III randomized study. Lung Cancer49(Suppl. 2), S35 (2005) (Abstract 0–098).
   Google Scholar
• D’Addario G, Pintilie M, Leithl NB et al. Platinum-based versus non-platinum-based chemotherapy in advanced non small-cell lung cancer: a meta-analysis of the published literature. J. Clin. Oncol.23(13), 2926–2936 (2005).
   PubMed Web of Science ®Google Scholar
• Niho S, Kubota K, Goto K et al. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a Phase I/II trial. Cancer Chemother. Pharmacol.52(1), 19–24 (2003).
   PubMedGoogle Scholar
• Takeda K, Negoro S, Tamura T et al. Docetaxel (D) versus docetaxel plus gemcitabine (DG) for second-line treatment of non-small cell lung cancer (NSCLC): results of a JCOG randomized trial (JCOG0104). J. Clin. Oncol.22(Suppl. 14), 625s (2004).
   Google Scholar
• Chen YM, Perng RP, Lin WC, Wu HW, Tsai CM, Whang-Peng J. Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy. Am. J. Clin. Oncol.25(5), 509–512 (2002).
   PubMedGoogle Scholar
• Kouroussis C, Mavroudis D, Kakolyris S et al. High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study. Lung Cancer44(3), 363–368 (2004).
   PubMed Web of Science ®Google Scholar
• Langer CJ, Vancel M, Schiller J et al. Age-specific subanalysis of ECOG 1594: Fit elderly patients (70–80 yrs) with NSCLC do as well as younger PTS (<70 years). Proc. Am. Soc. Clin. Oncol.22, 639 (2003) (Abstract 2571).
   Google Scholar
• Lilenbaum RC, Herndon IE, List M et al. Single agent versus combination chemotherapy in patients with advanced non small ceil lung cancer: a CALGB randomized trial of efficacy, quality of life and cost-effectiveness. J. Clin. Oncol.23(1), 190–196 (2005).
   PubMed Web of Science ®Google Scholar
• No authors listed. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J. Natl Cancer Inst.91, 66–72 (1999).
   PubMed Web of Science ®Google Scholar
• Gridelli C, Perrone F, Gallo C et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III randomized trial. J. Natl Cancer Inst.95, 362–372 (2003).
   PubMed Web of Science ®Google Scholar
• Fossella F, Belani CP. Phase III study (TAX 326) of docetaxel–cisplatin and docetaxel–carboplatin versus vinorelbine–cisplatin for the first-line treatment of advanced/metastatic non-small cell lung cancer: analyses in elderly patients. Cancer104(12), 2766–2766 (2005).
   Google Scholar
• Kudoh S, Takeda K, Nakagawa K et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J. Clin. Oncol.24, 3657–3663 (2006).
   PubMed Web of Science ®Google Scholar
• Karampeazis L, Vamvakas A, Agelidou A et al. Docetaxel compared with vinorelbine in elderly patients with advanced non-small cell lung cancer (NSCLC): a randomized Phase II Hellenic Oncology Research Group trial. 2007 ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol.25(18 Suppl.), (2007) (Abstract 7615).
   Google Scholar
• Weiss GJ, Langer C, Rosell R et al. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized Phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J. Clin. Oncol.24(27), 4405–4411 (2006).
   PubMed Web of Science ®Google Scholar
• Tibaldi C, Bernardini I, Chella A et al. Second-line chemotherapy with a modified schedule of docetaxel in elderly patients with advanced-stage non-small-cell lung cancer. Clin. Lung Cancer7(6), 401–405 (2006).
   Google Scholar
• Langer CJ, Vangel M, Schiller J et al. Age-specific subanalysis of ECOG 1594: fit elderly patients (70–80 YRS) with NSCLC do as well as younger pts (< 70). Proc. Am. Soc. Clin. Oncol.22, 639 (2003) (Abstract 2569).
   Google Scholar
• Langer C, Li S, Schiller J et al. Randomized Phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599. J. Clin. Oncol.25(4), 418–423 (2006).
   Google Scholar
• Baka S, Ashcroft L, Anderson H et al. Randomized Phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status ≤ 70) and advanced non-small-cell lung cancer. J. Clin. Oncol.23(10), 2136–2144 (2005).
   Google Scholar
• Leong SS, Toh CK, Lim WT et al. A randomized Phase II trial of single-agent gemcitabine, vinorelbine, or docetaxel in patients with advanced non-small cell lung cancer who have poor performance status and/or are elderly. J. Thorac. Oncol.2(3), 230–236 (2007).
   PubMed Web of Science ®Google Scholar
• Lilenbaum R, Rubin M, Samuel J et al. A randomized Phase II trial of two schedules of docetaxel in elderly or poor performance status patients with advanced non-small cell lung cancer. J. Thorac. Oncol.2(4), 306–311 (2007).
   PubMed Web of Science ®Google Scholar
• Belani CP, Ramalingam S, Schreeder M et al. Phase II study of cetuximab in combination with carboplatin and docetaxel for patients with advanced/ metastatic non-small cell lung cancer (NSCLC). J. Clin. Oncol. 2007 ASCO Annual Meeting Proceedings 25(Suppl. Pt I) 18S 7643 (2007).
   Google Scholar
• Manegold C, Gatzemeier U, Buchholz E, Smith RP, Fandi A. A pilot trial of gefitinib in combination with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer. Clin. Lung Cancer6(6), 343–349, (2005).
   Google Scholar
• Fandi A, Gatzemeier U, Smith R, Averbuch S, Manegold C. Final data from a pilot trial of gefitinib (ZD1839) in combination with docetaxel in patients with advanced or metastatic non-small-cell lung cancer (NSCLC): safety and pharmacokinetics. Proc. Am. Soc. Clin. Oncol.22, 655 (2003) (Abstract 2635).
   Google Scholar
• Rixe O, Lemarie E, Chomy F et al. Phase II combination of gefitinib (ZD1839) and docetaxel for non-small-cell-lung cancer (NSCLC): clinical results and biological monitoring. Proc. Am. Soc. Clin. Oncol.22, 661 (2003) (Abstract 2659).
   Google Scholar
• Fanucchi MP, Fossella FV, Belt R et al. Randomized Phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J. Clin. Oncol.24(31), 5025–5033 (2006).
   PubMed Web of Science ®Google Scholar
• Csiki I, Morrow JD, Sandler A et al. Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a Phase II trial of celecoxib and docetaxel. Clin. Cancer Res.11(18), 6634–6640 (2005).
   PubMed Web of Science ®Google Scholar
• Nugent FW, Mertens WC, Graziano S et al. Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter Phase II trial. Lung Cancer48(2), 267–273 (2005).
   PubMed Web of Science ®Google Scholar
• Heymach JV, Johnson BE, Prager D et al. Randomized, placebo-controlled Phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J. Clin. Oncol.25(27), 4270–4277 (2007).
   PubMed Web of Science ®Google Scholar
• Fujino S, Asada Y, Nakano Y et al. A Phase II study of nedaplatin (CDGP) and docetaxel (TXT) in patients with advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 2007 ASCO Annual Meeting Proceedings 25(Suppl. Pt1) 18S 7660 (2007).
   Google Scholar
• Sandler A, Gray R, Perry MC et al. Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med.355(24), 2542–2550 (2006).
   PubMed Web of Science ®Google Scholar
• William WN, Kies MS, Fossella FV et al. Phase II study of bevacizumab in combination with docetaxel and carboplatin in patients with metastatic non-small cell lung cancer (NSCLC). J. Clin. Oncol. 2007 ASCO Annual Meeting Proceedings 25(Suppl. Pt 1) 18S 18098 (2007).
   Google Scholar
• Vansteenkiste J, Lara PN Jr, Le Chevalier T et al. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J. Clin. Oncol.25(23), 3448–3455 (2007).
   PubMed Web of Science ®Google Scholar
• Stinchcombe TE. Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel. Nanomed.4, 415–423 (2007).
   Google Scholar
• Laack E, Dierlamm T, Knuffmann C et al. Docetaxel and carboplatin as second-line chemotherapy for metastatic non-small cell lung cancer. Lung Cancer36(3), 309–311 (2002).
   Google Scholar
• Rizvi NA, Riely GJ, Azzoli CG et al. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. J. Clin. Oncol.26(4), 639–643 (2008).
   PubMed Web of Science ®Google Scholar
• Azzoli CG, Krug LM, Miller VA et al. A Phase II tolerability study of cisplatin plus docetaxel as adjuvant chemotherapy for resected non-small cell lung cancer. J. Thorac. Oncol.2(7), 638–644 (2007).
   PubMed Web of Science ®Google Scholar
• Lilenbaum RC, Schwartz MA, Seigel L et al. Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinoma. Cancer92(8), 2158–2163 (2001).
   PubMed Web of Science ®Google Scholar
• Ardizzoia A, Acquati M, Fagnani D et al. Second line therapy with weekly low-dose docetaxel for pretreated non-small-cell lung carcinoma patients: a multicenter Italian Phase II study. Lung182(1), 1–8 (2004).
   PubMedGoogle Scholar
• Esteban E, Gonzalez de Sande L, Fernandez Y et al. Prospective randomised Phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. Ann. Oncol.14(11), 1640–1647 (2003).
   PubMedGoogle Scholar
• Petrioli R, Pozzessere D, Messinese S et al. Weekly low-dose docetaxel in advanced non-small cell lung cancer previously treated with two chemotherapy regimens. Lung Cancer39(1), 85–89 (2003).
   PubMedGoogle Scholar
• Serke M, Schoenfeld N, Loddenkemper R. Weekly docetaxel as second-line chemotherapy in advanced non-small cell lung cancer: Phase II trial. Anticancer Res.24(2C), 1211–1216 (2004).
   PubMedGoogle Scholar
• Rossi D, Graziano F, Ugolini M et al. Weekly docetaxel as second-line therapy in non-small cell lung cancer: a Phase II study. Tumori90(1), 50–53 (2004).
   PubMedGoogle Scholar
• Vazquez S, Grande C, Amenedo M et al. Biweekly docetaxel as second-line chemotherapy of patients with advanced non-small cell lung cancer: a Phase II study of the Galician Lung Cancer Group (GGCP 006–00). Anticancer Drugs15(5), 489–494 (2004).
   PubMedGoogle Scholar
• Chen Y-M, Shih J-F, Tsai C-M, Perng R-P, Whang-Peng J. A randomized trial of different docetaxel schedules in non-small cell lung cancer patients failing previous chemotherapy. Chest129(4), 840–842 (2006).
   Google Scholar
• Millward MJ, Boyer MJ, Lehnert M et al. Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a Phase II study in Caucasian and Asian patients. Ann. Oncol.14(3), 449–454 (2003).
   PubMed Web of Science ®Google Scholar
• Georgoulias V, Androulakis N, Dimopoulos AM et al. First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: a multicenter Phase II study. Ann. Oncol.9(3), 331–334 (1998).
   PubMedGoogle Scholar
• Le Chevalier T, Monnier A, Douillard JY et al. Docetaxel (Taxotere) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer. Eur. J. Cancer34(13), 2032–2036 (1998). Lee JJ, Han JY, Lee DH et al. A Phase II trial of docetaxel plus capecitabine in patients with previously treated non-small cell lung cancer. J. Clin. Pathol.58(6), 650–654 (2005).
   PubMed Web of Science ®Google Scholar
• Lee JJ, Han JY, Lee DH et al. A Phase II trial of docetaxel plus capecitabine in patients with previously treated non-small cell lung cancer. J. Clin. Pathol.58(6), 650–654 (2005).
   Google Scholar
• Raez LE, Santos ES, Lopes G et al. Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC). Lung Cancer53(3), 347–353 (2006).
   PubMed Web of Science ®Google Scholar
• Chen YM, Shih JF, Lee CS et al. Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel. Lung Cancer39(2), 209–214 (2003).
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Fukuoka M, Negoro SI et al. Randomised Phase II study of docetaxel/cisplatin vs. docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803). Br. J. Cancer90(1), 87–92 (2004).
   PubMed Web of Science ®Google Scholar
• Seto T, Takezako Y, Nakamura H et al. Doublet regimen of cisplatin plus docetaxel for second-line chemotherapy after prior therapy with cisplatin plus irinotecan for non-small cell lung cancer: a Phase II study. Int. J. Clin. Oncol.9(5), 378–382 (2004).
   Google Scholar
• Grossi F, Fasola G, Rossetto C et al. Phase II study of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 007). Lung Cancer52(1), 89–92 (2006).
   Google Scholar
• Leu KM, Kim KM, Larson M et al. Phase I/II trial of docetaxel and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. Lung Cancer34(1), 105–113 (2001).
   PubMed Web of Science ®Google Scholar